Asthma Comparative Effectiveness Study - Asthma CER

Study identifier:RWE-000015

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A U.S. retrospective database analysis evaluating the comparative effectiveness of budesonide/formoterol combination (BFC) and fluticasone propionate/salmeterol Combination (FSC) among asthma patients

Medical condition

asthma

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

6086

Study type

Observational

Age

12 Years - 64 Years

Date

Study Start Date: 01 Jun 2012

Primary Completion Date: 01 Jul 2012

Study Completion Date: 01 Sept 2012

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Symbicort BFC patients new to ICS/LABA combination therapy	-
Advair FSC patients new to ICS/LABA combination therapy	-

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1091&filename=CSR-RWE-000015.pdf
Download
CSR-RWE-000015.pdf
Download
Trial Results Summaries
Available here

Asthma Comparative Effectiveness Study - Asthma CER

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1091&filename=CSR-RWE-000015.pdf

CSR-RWE-000015.pdf

Trial Results Summaries